rs2284367
|
|
Catalase measurement
|
C |
0.700 |
GeneticVariation
|
GWASCAT |
Connecting genetic risk to disease end points through the human blood plasma proteome.
|
28240269 |
2017 |
rs7933285
|
|
Blood Protein Measurement
|
C |
0.700 |
GeneticVariation
|
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
rs1001179
|
|
Glaucoma, Primary Open Angle
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, no association was found for rs1001179 and rs7943316 with POAG.
|
28829657 |
2018 |
rs1001179
|
|
Diabetes Mellitus, Insulin-Dependent
|
|
0.020 |
GeneticVariation
|
BEFREE |
There was no significant association between the CAT gene SNP rs1001179 and T1D or DPN.
|
29924645 |
2018 |
rs1001179
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect of MnSOD (p.Val16Ala, rs4880) and CAT (-262C>T, rs1001179) SNPs on the association between the MD and BC risk in the case-control study of BC MASTOS in Cyprus.
|
26130326 |
2016 |
rs1001179
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect of MnSOD (p.Val16Ala, rs4880) and CAT (-262C>T, rs1001179) SNPs on the association between the MD and BC risk in the case-control study of BC MASTOS in Cyprus.
|
26130326 |
2016 |
rs1001179
|
|
Glaucoma, Primary Open Angle
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis of catalase SNP rs1001179 in Saudi patients with primary open angle glaucoma.
|
24215654 |
2013 |
rs1001179
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Highly active women harboring variant alleles in CAT rs1001179 were at increased risk of breast cancer compared with women with the common CC genotype (OR = 1.61; 95 % CI, 1.06-2.45).
|
23053794 |
2012 |
rs1001179
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Highly active women harboring variant alleles in CAT rs1001179 were at increased risk of breast cancer compared with women with the common CC genotype (OR = 1.61; 95 % CI, 1.06-2.45).
|
23053794 |
2012 |
rs1001179
|
|
Diabetes Mellitus, Insulin-Dependent
|
|
0.020 |
GeneticVariation
|
BEFREE |
Major effects of two SNPs, C1167T (rs769217) and C(-262)T (rs1001179), of the catalase gene on T1D susceptibility have been reported previously in Russians from Moscow.
|
16453382 |
2006 |
rs1212131663
|
|
Acatalasia
|
|
0.020 |
GeneticVariation
|
BEFREE |
This method was sensitive for detection of G113A acatalasemia mutation, but poorly detected C37T and G5A acatalasemia mutations.
|
22286031 |
2012 |
rs1212131663
|
|
Acatalasia
|
|
0.020 |
GeneticVariation
|
BEFREE |
The detection of a novel acatalasemia mutation (37C>T in exon 9) and the 113G>A (exon 9) mutation in Hungary are further proofs of genetic heterogeneity origin of acatalasemia mutations.
|
21947853 |
2012 |
rs1001179
|
|
Dyskinetic syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, clinical-pharmacogenetic model for prediction of time to occurrence of dyskinesia included female sex (HR = 1.07), age at diagnosis (HR = 0.97), tremor-predominant Parkinson's disease (HR = 0.88), beta-blockers (HR = 0.95), alcohol consumption (HR = 0.99), time from diagnosis to initiation of levodopa treatment (HR = 1.15), <i>CAT</i> rs1001179 (HR = 1.27), <i>SOD2</i> rs4880 (HR = 0.95), <i>NOS1</i> rs2293054 (HR = 0.99), <i>COMT</i> rs165815 (HR = 0.92), and <i>SLC22A1</i> rs628031 (HR = 0.80).
|
31156712 |
2019 |
rs1001179
|
|
Parkinson Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, clinical-pharmacogenetic model for prediction of time to occurrence of dyskinesia included female sex (HR = 1.07), age at diagnosis (HR = 0.97), tremor-predominant Parkinson's disease (HR = 0.88), beta-blockers (HR = 0.95), alcohol consumption (HR = 0.99), time from diagnosis to initiation of levodopa treatment (HR = 1.15), <i>CAT</i> rs1001179 (HR = 1.27), <i>SOD2</i> rs4880 (HR = 0.95), <i>NOS1</i> rs2293054 (HR = 0.99), <i>COMT</i> rs165815 (HR = 0.92), and <i>SLC22A1</i> rs628031 (HR = 0.80).
|
31156712 |
2019 |
rs1001179
|
|
Chronic Obstructive Airway Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotyping of superoxide dismutase 1 (SOD1) + 35 A/C (rs2234694), catalase [A-21T (rs7943316), C-262T (rs1001179)] and glutathione peroxidase 1 (reduced glutathione (GSH)-Px1) 198Pro/Leu (rs1050450) was carried out in 143 patients with COPD and 216 healthy controls using PCR-RFLP.
|
30668180 |
2019 |
rs1001179
|
|
Diabetic peripheral neuropathy
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of our study was to investigate possible associations between three SNPs: rs4673 in the CYBA gene; rs1041740 in the SOD1 gene; and rs1001179 in the CAT gene, and type 1 diabetes (T1D) or diabetic peripheral neuropathy (DPN) in T1D patients.
|
29924645 |
2018 |
rs1001179
|
|
Polycystic Ovary Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
GPx1 (rs1050450), MnSOD (rs4880), and CAT (rs1001179) variants might not be a risk factor for PCOS.
|
30206965 |
2018 |
rs1001179
|
|
Malignant mesothelioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Although there was no independent association between either <i>CAT</i> rs1001179 or <i>hOGG1</i> rs1052133 polymorphism and malignant mesothelioma, interaction between both polymorphisms showed a protective effect, OR<sub>int</sub> 0.27 (95% CI 0.10-0.77).
|
29520212 |
2018 |
rs1001179
|
|
Vitiligo
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aims were (i) to assess erythrocyte CAT enzyme activity and lipid peroxidation (LPO) levels as well as CAT mRNA expression in skin and blood; (ii) to investigate CAT gene promoter rs7943316, rs1001179, 5'-untranslated region rs1049982, and exon (rs17886350, rs11032709, rs17880442, rs35677492) polymorphisms; and (iii) to perform genotype/haplotype-phenotype correlation analyses in patients with vitiligo and controls from Gujarat.
|
28542879 |
2017 |
rs1001179
|
|
Alcohol abuse
|
|
0.010 |
GeneticVariation
|
BEFREE |
Using an established PCR-RFLP method for genotyping, we examined the association of rs1001179 with glycated hemoglobin (HbA1c) and plasma lipids using univariate analyses with age, sex, body mass index (BMI), smoking, and alcohol abuse as covariates, in a group of dyslipidemic patients from northern Greece.
|
27704307 |
2017 |
rs1001179
|
|
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aims were (i) to assess erythrocyte CAT enzyme activity and lipid peroxidation (LPO) levels as well as CAT mRNA expression in skin and blood; (ii) to investigate CAT gene promoter rs7943316, rs1001179, 5'-untranslated region rs1049982, and exon (rs17886350, rs11032709, rs17880442, rs35677492) polymorphisms; and (iii) to perform genotype/haplotype-phenotype correlation analyses in patients with vitiligo and controls from Gujarat.
|
28542879 |
2017 |
rs1001179
|
|
Hypoxic-Ischemic Encephalopathy
|
|
0.010 |
GeneticVariation
|
BEFREE |
CAT rs1001179 polymorphism could be used to identify children that have a higher susceptibility to cerebral palsy after perinatal HIE.
|
27302388 |
2016 |
rs1001179
|
|
Fibrosis, Liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study aimed to investigate the association of genetic polymorphisms of CAT C-262T (rs1001179) and GPX1 Pro198Leu (rs1050450) with different stages of liver fibrosis and development of hepatocellular carcinoma (HCC).
|
26990426 |
2016 |
rs1001179
|
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results demonstrated that the rs1001179 polymorphism was associated with an increased cancer risk in the recessive and homozygote models (TT vs. CC: OR = 1.19, P = 0.01; TT vs. CT+CC: OR = 1.19, P <0.001).
|
27449288 |
2016 |
rs1001179
|
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analyses revealed a significant association between the rs1001179 polymorphism and prostate cancer in all models except the homozygote comparison.
|
27449288 |
2016 |